Q-omics provides the consensus-scored RPA3P2 profile across patient tissues and cancer cell-line models. RPA3P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPA3P2 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, RPA3P2 RNA expression shows 5,207 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, THCA, and STAD as cancer lineages where RPA3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPA3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPA3P2 survival associations across molecular data types. RPA3P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPA3P2 RNA expression–survival associations across cancer types. High RPA3P2 expression shows unfavorable associations in ACC, LUSC and MESO, but favorable associations in HNSC, READ and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for RPA3P2 RNA expression.
This table summarizes RPA3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPA3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPA3P2 shows lower tumor expression in THCA and CHOL and higher tumor expression in BRCA, KIRC and LIHC. The THCA box plot shows higher RPA3P2 RNA expression in normal versus tumor tissue (log2 FC = −1.379, t-test p < 0.001).
This table shows molecular features associated with RPA3P2 in patient tissues and cancer cell lines. In patient samples, RPA3P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
